within Pharmacolibrary.Drugs.ATC.V;

model V04CE01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 60 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.00035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Galactose is a monosaccharide sugar, part of the lactose disaccharide found in milk. It is used rarely as a diagnostic agent for liver function and galactose metabolism disorders, but is not an approved medication for therapeutic use in most countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy individuals. No definitive PK profile reported in literature for therapeutic use; estimates derived based on monosaccharide similarities and diagnostic use.</p><h4>References</h4><ol><li><p>Davies, R, et al., &amp; Dillon, SR (2024). A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults. <i>Clinical and translational science</i> 17(11) e70055–None. DOI:<a href=&quot;https://doi.org/10.1111/cts.70055&quot;>10.1111/cts.70055</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39494621/&quot;>https://pubmed.ncbi.nlm.nih.gov/39494621</a></p></li><li><p>Bird, PH, &amp; Hartmann, PE (1994). The response in the blood of piglets to oral doses of galactose and glucose and intravenous administration of galactose. <i>The British journal of nutrition</i> 71(4) 553–561. DOI:<a href=&quot;https://doi.org/10.1079/bjn19940162&quot;>10.1079/bjn19940162</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8011608/&quot;>https://pubmed.ncbi.nlm.nih.gov/8011608</a></p></li><li><p>Wu, W, et al., &amp; Wu, Q (2014). Pharmacokinetics of liver-targeted docetaxel liposomes modified with 6-. <i>Biomedical reports</i> 2(4) 545–548. DOI:<a href=&quot;https://doi.org/10.3892/br.2014.285&quot;>10.3892/br.2014.285</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24944805/&quot;>https://pubmed.ncbi.nlm.nih.gov/24944805</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V04CE01;
